Compounds > estradiol-17 beta-3-methyl ether
Page last updated: 2024-12-08

estradiol-17 beta-3-methyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methoxyestradiol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID246206
CHEMBL ID116468
SCHEMBL ID547265
MeSH IDM0083869

Synonyms (63)

Synonym
nsc 58851
(17-beta)-3-methoxyestra-1,3,5(10)-trien-17-ol
17beta-estradiol 3-methyl ether
estra-1,3,5(10)-trien-17-ol, 3-methoxy-, (17-beta)-
oestradiol 3-methyl ether
3-methoxyoestra-1,3,5(10)-trien-17-beta-ol
estra-1,3,5(10)-trien-17-beta-ol, 3-methoxy-
estra-1,3,5(10)-trien-17-ol, 3-methoxy-
3-methoxy-estra-1,3,5(10)-triene-17-beta-ol
estra-1,3,5(10)-trien-17beta-ol, 3-methoxy-
einecs 213-858-8
3-methoxyestra-1,3,5(10)-trien-17-beta-ol
estradiol-17beta-3-methyl ether
3-methoxyoestradiol
nsc-58851
17.beta.-estradiol 3-methyl ether
estra-1,5(10)-trien-17.beta.-ol, 3-methoxy-
1035-77-4
estradiol 3-methyl ether
estra-1,5(10)-trien-17-ol, 3-methoxy-, (17.beta.)-
nsc58851
CHEMBL116468
(8r,9s,13s,14s,17s)-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol
0bq383g656 ,
unii-0bq383g656
AKOS015969773
3-methoxyestradiol
3-o-methyl estradiol
SCHEMBL547265
3-methoxyestra-1,3,5(10)-trien-17beta-ol
3-o-methylestradiol
3-methoxyestra-1,3,5(10)-trien-17-ol #
3-methoxy-estra-1,3,5(10)-triene-17-.beta.-ol
estra-1,3,5(10)-trien-17.beta.-ol, 3-methoxy-
estra-1,3,5(10)-trien-17-ol, 3-methoxy-, (17.beta.)-
3-methoxyestra-1,3,5(10)-trien-17.beta.-ol
estra-1,3,5(10)-trien-17-ol, 3-methoxy-, (17beta)-
17.beta.-hydroxy-3-methoxyestra-1,3,5(10)-triene
3-methoxyestra-1,3,5(10)-trien-17-.beta.-ol
3-methoxyoestra-1,3,5(10)-trien-17.beta.-ol
.beta.-estradiol, 3-methyl ether
estra-1,3,5(10)-trien-17-ol,3-methoxy-,(17b)-
3-methoxyoestra-1,3,5(10)-trien-17-.beta.-ol
estradiol-17.beta.-3-methyl ether
estra-1,3,5(10)-trien-17-.beta.-ol, 3-methoxy-
(17-.beta.)-3-methoxyestra-1,3,5(10)-trien-17-ol
3-methoxy-13.beta.-methyl-1,3,5(10)-gonatrien-17.beta.-ol
estra-1,3,5(10)-trien-17-ol, 3-methoxy-, (17-.beta.)-
3-methoxy-17.beta.-hydroxyestra-1,3,5(10)-triene
J-001003
3-methoxy-17b-hydroxyestra-1,3,5(10)-triene
(8r,9s,13s,14s,17s)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-17-ol
VS-13619
(1s,3as,3br,9bs,11as)-7-methoxy-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-ol
STL559048
BBL036669
(17beta)-3-methoxyestra-1,3,5(10)-trien-17-ol
Q27236583
(8r,13s,17s)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-17-ol
DTXSID001313230
gtpl11860
17beta-estradiol methyl ether
pru-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID45078Percent change in 17-beta-estradiol mediated transcriptional activation in CHO cells expressing human estrogen receptor alpha at 10e-7 M2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Identification of "latent hits" in compound screening collections.
AID1131358Displacement of [3H]-estradiol from estrogen receptor in rat uterine cytosol at 10'-5 to 10'-10 M after 16 hrs relative to estradiol1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/-)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hexestrol
[no description available]		1.9510stilbenoid
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.0210chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
boldenone
boldenone: RN given refers to (17beta)-isomer. boldenone : An 3-oxo-Delta(1),Delta(4)-steroid substituted by an oxo group at position 3 and a beta-hydroxy group at position 17. It is an anabolic androgenic steroid that has been developed for veterinary use.		2.021017beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
anabolic androgenic steroid
equilenin
Equilenin: An estrogenic steroid produced by HORSES. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the URINE of pregnant mares.. equilenin : A 3-hydroxy steroid that is estrone which carries two double bonds at positions 6 and 8. It is found in the urine of pregnant mare's and extensively used for estrogen replacement therapy in postmenopausal women.		2.021017-oxo steroid;
3-hydroxy steroid		antioxidant;
mammalian metabolite
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.0110olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310